[go: up one dir, main page]

TN2009000510A1 - Extended release formulation of nevirapine - Google Patents

Extended release formulation of nevirapine

Info

Publication number
TN2009000510A1
TN2009000510A1 TNP2009000510A TN2009000510A TN2009000510A1 TN 2009000510 A1 TN2009000510 A1 TN 2009000510A1 TN P2009000510 A TNP2009000510 A TN P2009000510A TN 2009000510 A TN2009000510 A TN 2009000510A TN 2009000510 A1 TN2009000510 A1 TN 2009000510A1
Authority
TN
Tunisia
Prior art keywords
nevirapine
extended release
release formulation
pharmaceutical composition
relates
Prior art date
Application number
TNP2009000510A
Other languages
French (fr)
Inventor
Michael L Cappolla
Sveltana Sienkiewicz
Glenn Charles Snow
Feng-Jing Chen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39739795&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2009000510(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TN2009000510A1 publication Critical patent/TN2009000510A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

the invention relates to an extended release pharmaceutical composition comprising nevirapine.
TNP2009000510A 2007-06-08 2009-12-04 Extended release formulation of nevirapine TN2009000510A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94276507P 2007-06-08 2007-06-08
PCT/US2008/065705 WO2008154234A2 (en) 2007-06-08 2008-06-04 Extended release formulation of nevirapine

Publications (1)

Publication Number Publication Date
TN2009000510A1 true TN2009000510A1 (en) 2011-03-31

Family

ID=39739795

Family Applications (1)

Application Number Title Priority Date Filing Date
TNP2009000510A TN2009000510A1 (en) 2007-06-08 2009-12-04 Extended release formulation of nevirapine

Country Status (28)

Country Link
US (1) US8460704B2 (en)
EP (1) EP2155169B1 (en)
JP (1) JP5417662B2 (en)
KR (1) KR101017862B1 (en)
CN (1) CN101784263B (en)
AR (1) AR066924A1 (en)
AU (1) AU2008262031B2 (en)
BR (1) BRPI0811732A2 (en)
CA (1) CA2687491C (en)
CL (1) CL2008001678A1 (en)
CO (1) CO6150128A2 (en)
DK (1) DK2155169T3 (en)
EA (1) EA018377B1 (en)
EC (1) ECSP099561A (en)
ES (1) ES2574836T3 (en)
HU (1) HUE028598T2 (en)
IL (1) IL199924A0 (en)
MA (1) MA31430B1 (en)
MX (1) MX2009007764A (en)
NZ (1) NZ578664A (en)
PE (2) PE20131035A1 (en)
PL (1) PL2155169T3 (en)
TN (1) TN2009000510A1 (en)
TW (1) TWI419716B (en)
UA (1) UA97971C2 (en)
UY (1) UY31128A1 (en)
WO (1) WO2008154234A2 (en)
ZA (1) ZA200904939B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY149159A (en) 2005-11-15 2013-07-31 Hoffmann La Roche Method for treating joint damage
US20130172274A1 (en) 2005-12-20 2013-07-04 Duke University Methods and compositions for delivering active agents with enhanced pharmacological properties
DK2155169T3 (en) 2007-06-08 2016-06-13 Boehringer Ingelheim Int Formulation of nevirapine extended release
EP2926825A1 (en) 2008-06-27 2015-10-07 Duke University Therapeutic agents comprising elastin-like peptides
US20140193491A1 (en) 2011-05-30 2014-07-10 Cipla Limited Pharmaceutical antiretroviral composition
WO2013028989A1 (en) * 2011-08-24 2013-02-28 Phasebio Pharmaceuticals, Inc. Formulations of active agents for sustained release
WO2013132208A1 (en) * 2012-03-05 2013-09-12 Cipla Limited Pharmaceutical antiretroviral combinations comprising lamivudine, festinavir and nevirapine
CN104523630B (en) * 2015-01-22 2017-08-25 山东新时代药业有限公司 A kind of NVP tablet
EP3153157A1 (en) 2015-10-09 2017-04-12 Teva Pharmaceutical Works Private Limited Company Pharmaceutical composition for prolonged release of nevirapine

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5366972A (en) 1989-04-20 1994-11-22 Boehringer Ingelheim Pharmaceuticals, Inc. 5,11-dihydro-6H-dipyrido(3,2-B:2',3'-E)(1,4)diazepines and their use in the prevention or treatment of HIV infection
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
CA2030056C (en) 1989-11-17 1995-10-17 Karl D. Hargrave 5,11-dihydro-6h-dipyrido[3,2-b:2',3'-e][1,4]diazepines and their use in the prevention or treatment of hiv infection
US5419917A (en) * 1994-02-14 1995-05-30 Andrx Pharmaceuticals, Inc. Controlled release hydrogel formulation
US6514530B2 (en) * 1997-09-09 2003-02-04 Alza Corporation Dosage form comprising means for changing drug delivery shape
PT1035834E (en) 1997-12-05 2002-09-30 Alza Corp OSMOTIC DOSE FORMAT COMPREHENDING FIRST AND SECOND COATINGS
MXPA01006108A (en) 1998-12-17 2002-09-18 Alza Corp Conversion of liquid filled gelatin capsules into controlled release systems by multiple coatings.
IL145661A0 (en) * 1999-03-31 2002-06-30 Janssen Pharmaceutica Nv Pregelatinized starch in a controlled release formulation
AU775360B2 (en) * 1999-09-24 2004-07-29 Janssen Pharmaceutica N.V. Antiviral compositions
WO2001041742A2 (en) 1999-12-09 2001-06-14 Alza Corporation Antiviral medication
US6541014B2 (en) * 2000-10-13 2003-04-01 Advancis Pharmaceutical Corp. Antiviral product, use and formulation thereof
WO2002092095A1 (en) 2001-05-11 2002-11-21 Boehringer Ingelheim International Gmbh Use of nevirapine to treat or prevent lipid pathology in patients with hiv that is resistant to nevirapine
US20030050620A1 (en) 2001-09-07 2003-03-13 Isa Odidi Combinatorial type controlled release drug delivery device
AU2003287666A1 (en) 2002-11-13 2004-06-03 Control Delivery Systems, Inc. Systemic delivery of antiviral agents
US20070259014A1 (en) 2003-06-20 2007-11-08 Vgx Pharmaceuticals, Inc. Compositions for and Methods for Treating Hiv
WO2005048978A2 (en) 2003-10-01 2005-06-02 Lupin Limited A controlled release pharmaceutical composition and a process for preparing the same
PT1696822E (en) 2003-11-13 2010-04-28 Psivida Inc Injectable sustained release implant having a bioerodible matrix core and a bioerodible skin
KR101284361B1 (en) * 2004-09-02 2013-07-15 얀센 파마슈티카 엔.브이. Hydrochloride of 4-((4-(4-(2-cyanoethenyl)-2,6-dimethylphenyl)amino)-2-pyrimidinyl)amino)benzonitrile
WO2006114709A1 (en) * 2005-04-25 2006-11-02 Aurobindo Pharma Limited Pharmaceutical compositions of antiretrovirals
RS20070512A (en) 2005-06-29 2009-01-22 Panacea Biotec Ltd., Pharmaceutical sustained release compositionsand processes thereof
WO2007052289A2 (en) 2005-07-22 2007-05-10 Rubicon Research Pvt Ltd. Novel dispersible tablet composition
FR2891459B1 (en) 2005-09-30 2007-12-28 Flamel Technologies Sa MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE INGREDIENT AND ORAL GALENIC FORM COMPRISING THE SAME
JP2009511191A (en) * 2005-10-14 2009-03-19 マイクロドース・テクノロジーズ・インコーポレーテッド Orally administered drug package method
DK2155169T3 (en) 2007-06-08 2016-06-13 Boehringer Ingelheim Int Formulation of nevirapine extended release

Also Published As

Publication number Publication date
BRPI0811732A2 (en) 2014-11-18
EP2155169B1 (en) 2016-03-23
WO2008154234A9 (en) 2009-11-26
CN101784263A (en) 2010-07-21
CO6150128A2 (en) 2010-04-20
EP2155169A2 (en) 2010-02-24
IL199924A0 (en) 2010-04-15
PE20131035A1 (en) 2013-10-01
MA31430B1 (en) 2010-06-01
UA97971C2 (en) 2012-04-10
EA018377B1 (en) 2013-07-30
HK1145806A1 (en) 2011-05-06
CL2008001678A1 (en) 2009-09-11
HUE028598T2 (en) 2016-12-28
ECSP099561A (en) 2009-09-29
US8460704B2 (en) 2013-06-11
NZ578664A (en) 2011-11-25
WO2008154234A3 (en) 2010-01-21
US20100278918A1 (en) 2010-11-04
AR066924A1 (en) 2009-09-23
CA2687491C (en) 2011-09-20
TWI419716B (en) 2013-12-21
WO2008154234A2 (en) 2008-12-18
JP2010520891A (en) 2010-06-17
DK2155169T3 (en) 2016-06-13
TW200916127A (en) 2009-04-16
JP5417662B2 (en) 2014-02-19
PE20090371A1 (en) 2009-04-24
PL2155169T3 (en) 2016-09-30
CN101784263B (en) 2012-11-07
KR101017862B1 (en) 2011-03-04
UY31128A1 (en) 2009-01-30
EA200900958A1 (en) 2010-04-30
MX2009007764A (en) 2009-09-10
ZA200904939B (en) 2010-04-28
CA2687491A1 (en) 2008-12-18
AU2008262031A1 (en) 2008-12-18
AU2008262031B2 (en) 2011-08-25
KR20100020447A (en) 2010-02-22
ES2574836T3 (en) 2016-06-22

Similar Documents

Publication Publication Date Title
JOP20180102A1 (en) Pharmaceutical composition
TN2009000510A1 (en) Extended release formulation of nevirapine
MX2011007267A (en) Pharmaceutical compositions comprising 2-oxo-1-pyrrolidine derivatives.
MX2012007098A (en) Phenol derivatives and pharmaceutical or cosmetic use thereof.
PH12012501346A1 (en) Heteroaryl compounds and uses thereof
EA201101118A1 (en) PHARMACEUTICAL COMPOSITIONS, INCLUDING 2-OXO-1-PYRROLIDINE DERIVATIVES
MX2012007161A (en) Phenol derivatives and pharmaceutical or cosmetic use thereof.
IL224288A (en) Derivatives of substituted pyrazolamide, pharmaceutical compositions comprising the same and uses thereof
MX2011014019A (en) Diazahomoadamantane derivatives and methods of use thereof.
MY153915A (en) Organic compounds
WO2011032169A3 (en) Pharmaceutical compositions and formulations including inhibitors of the pleckstrin homology domain and methods for using same
SI2373681T1 (en) Pharmaceutical compositions of albiglutide
PL2079446T3 (en) Paliperidone sustained release formulation
MX2009010174A (en) Azaadamantane ester and carbamate derivatives and methods of use thereof.
WO2009115084A3 (en) Pyrrolopyrimidine derivatives, and use thereof
IN2012DN03404A (en)
MX2010008852A (en) Formulations of flibanserin.
ZA201102652B (en) Pharmaceutical composition utilising combinations of variants of the gonadotropin-liberating hormane (gnrh) as immunogen
MX2009010176A (en) 4-substituted azaadamantane derivatives and methods of use thereof.
EP2296687A4 (en) Pharmaceutical compositions of somatostatin-dopamine conjugates
MY165088A (en) Pharmaceutical compositions comprising alisporivir
ZA201101053B (en) Pharmaceutical compositions of samatotrophic hormones
AP2012006119A0 (en) Pharmaceutical composition of isoniazid.
MX2012008253A (en) Pharmaceutical use of multicyclic compounds as anti-aids agents.
EP2568810A4 (en) Darunavir compositions